Stocktoria
Xenon Pharmaceuticals Inc. XENE
Xenon Pharmaceuticals Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $0 | $0 | $9.4M | $18.4M | $32.2M | $6.8M | — | $311,000 | $1.8M |
| R&D expense | $300.9M | $210.4M | $167.5M | $105.8M | $75.5M | $50.5M | $38.8M | $23.6M | $25.6M | $19.8M |
| Operating income | -$373.1M | -$279.3M | -$214.1M | -$129.1M | -$79.0M | -$31.3M | -$42.8M | -$38.0M | -$32.6M | -$24.8M |
| Interest expense | — | — | — | — | — | $484,000 | $1.4M | $1.4M | — | — |
| Income tax | $1.0M | -$4.1M | -$292,000 | $118,000 | -$6,000 | -$257,000 | -$23,000 | -$24,000 | — | — |
| Net income | -$345.9M | -$234.3M | -$182.4M | -$125.4M | -$78.9M | -$28.8M | -$41.6M | -$34.5M | -$30.7M | -$23.0M |
| EPS (diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | — | $-1.63 | $-1.72 | $-1.48 |
| Operating cash flow | -$279.1M | -$181.4M | -$151.1M | -$101.0M | -$69.5M | -$48.1M | -$4.7M | -$34.7M | -$28.7M | -$19.6M |
| Free cash flow | -$279.9M | -$184.5M | -$156.7M | -$103.9M | -$71.6M | -$50.8M | -$6.0M | -$35.2M | -$29.0M | -$19.8M |
| Cash & equivalents | $199.2M | $142.7M | $148.6M | $57.2M | $175.7M | $45.0M | $24.8M | $67.8M | $20.5M | $17.1M |
| Total assets | $633.2M | $798.1M | $964.8M | $754.1M | $572.0M | $189.2M | $147.7M | $122.4M | $46.1M | $67.5M |
| Total liabilities | $51.4M | $43.2M | $36.9M | $32.6M | $22.0M | $17.8M | $55.7M | $19.1M | $10.2M | $3.6M |
| Shareholders' equity | $581.8M | $754.9M | $927.9M | $721.5M | $550.0M | $171.4M | $92.0M | $103.3M | $35.9M | $63.9M |
Growth · year-over-year · Revenue CAGR 19.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | -100.0% | -48.8% | -42.7% | +371.0% | — | — | -82.8% | -88.4% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.